Results 71 to 80 of about 56,186 (320)

Rodent Models of Polycystic Ovary Syndrome [PDF]

, 2013
Rodents are clearly valuable models for assessing disruption of fertility. The effects of different steroid treatments at different stages of reproductive life through from fetal to adult have been assessed for effects on fertility, ovarian morphology ...
Duncan, Colin, McNeilly, Alan S
core   +1 more source

Real‐world progression‐free survival and overall survival in patients with HR+/HER2− advanced breast cancer treated in first‐line with ribociclib, endocrine monotherapy or chemotherapy: Results from the observational RIBANNA study

International Journal of Cancer, EarlyView.
What's New? The CDK4/6 inhibitor ribociclib in combination with an endocrine‐based therapy has demonstrated significant progression‐free and overall survival benefits in patients with advanced/metastatic HR+/HER2‐ breast cancer in the pivotal MONALEESA trials.
Peter A. Fasching, Cosima Brucker, Thomas Decker, Anne Engel, Thomas Göhler, Christian Jackisch, Jan Janssen, Andreas Köhler, Kerstin Lüdtke‐Heckenkamp, Diana Lüftner, Frederik Marmé, Marion van Mackelenbergh, Beate Rautenberg, Marcus Schmidt, Rudolf Weide, Pauline Wimberger, Elena Kisseleff, Christina Pfister, Claudia Quiering, Christian Roos, Achim Wöckel   +20 more
wiley   +1 more source

Effect of denosumab on bone mineral density in Japanese women with osteopenia treated with aromatase inhibitors for breast cancer: subgroup analyses of a Phase II study

Therapeutics and Clinical Risk Management, 2018
Katsuhiko Nakatsukasa,1 Hiroshi Koyama,2 Yoshimi Ouchi,1 Kouichi Sakaguchi,1 Yoshifumi Fujita,1 Takayuki Matsuda,3 Makoto Kato,4 Eiichi Konishi,5 Tetsuya Taguchi1 1Department of Endocrine and Breast Surgery, Kyoto Prefectural University of Medicine ...
Nakatsukasa K, Koyama H, Ouchi Y, Sakaguchi K, Fujita Y, Matsuda T, Kato M, Konishi E, Taguchi T   +8 more
doaj  

Antitumor activity of Z-endoxifen in aromatase inhibitor-sensitive and aromatase inhibitor-resistant estrogen receptor-positive breast cancer

Breast Cancer Research, 2020
Background The tamoxifen metabolite, Z-endoxifen, demonstrated promising antitumor activity in endocrine-resistant estrogen receptor-positive (ER+) breast cancer.
Swaathi Jayaraman, Xiaonan Hou, Mary J. Kuffel, Vera J. Suman, Tanya L. Hoskin, Kathryn E. Reinicke, David G. Monroe, Krishna R. Kalari, Xiaojia Tang, Megan A. Zeldenrust, Jingfei Cheng, Elizabeth S. Bruinsma, Sarah A. Buhrow, Renee M. McGovern, Stephanie L. Safgren, Chad A. Walden, Jodi M. Carter, Joel M. Reid, James N. Ingle, Matthew M. Ames, John R. Hawse, Matthew P. Goetz   +21 more
doaj   +1 more source

TRPA1 mediates aromatase inhibitor-evoked pain by the aromatase substrate androstenedione [PDF]

, 2016
Aromatase inhibitors (AI) induce painful musculoskeletal symptoms (AIMSS), which are dependent upon the pain transducing receptor TRPA1. However, as the AI concentrations required to engage TRPA1 in mice are higher than those found in the plasma of ...
Benemei, Silvia, Coppi, Elisabetta, De Logu, Francesco, Di Tommaso, Mariarosaria, Fusi, Camilla, Geppetti, Pierangelo, Li Puma, Simone, Marone, Ilaria M., Materazzi, Serena, Moneti, Gloriano, Morice, Alyn H., Nassini, Romina, Sadofsky, Laura R., Susini, Tommaso, Terreni, Alessandro, Tonello, Raquel   +15 more
core   +1 more source

Sequencing of aromatase inhibitors [PDF]

British Journal of Cancer, 2005
Since the development of the third-generation aromatase inhibitors (AIs), anastrozole, letrozole and exemestane, these agents have been the subject of intensive research to determine their optimal use in advanced breast cancer. Not only have they replaced progestins in second-line therapy and challenged the role of tamoxifen in first-line, but there is
openaire   +2 more sources

Long‐term benefit from adjuvant tamoxifen therapy for ER+ HER2− breast cancer by PR positivity

International Journal of Cancer, EarlyView.
What's New? Tamoxifen is a cornerstone of endocrine therapy for estrogen receptor (ER)‐positive/human epidermal growth factor receptor 2 (HER2)‐negative breast cancer. Its long‐term benefits, however, may vary by progesterone receptor (PR) status. Here, using data from the Stockholm tamoxifen trials, the authors evaluated whether PR expression predicts
Anna E. Nordenskjöld, Magdalena Ríos‐Romero, Huma Dar, Tommy Fornander, Gizeh Perez‐Tenorio, Helena Fohlin, Olle Stål, Julia Tutzauer, Linda S. Lindström   +8 more
wiley   +1 more source

Incidence of Comorbidities in Women with Breast Cancer Treated with Tamoxifen or an Aromatase Inhibitor: An Australian Population-Based Cohort Study

Journal of Comorbidity, 2018
Background The development of comorbidities has become increasingly relevant with longer-term cancer survival. Objective To assess the pattern of comorbidities among Australian women with breast cancer treated with tamoxifen or an aromatase inhibitor ...
Huah Shin Ng, Bogda Koczwara, David Roder, Theo Niyonsenga, Agnes Vitry   +4 more
doaj   +1 more source

Sexually Dimorphic Effects of Aromatase on Neurobehavioral Responses

Frontiers in Molecular Neuroscience, 2018
Aromatase is the enzyme responsible for converting testosterone to estradiol. In mammals, aromatase is expressed in the testes, ovaries, brain, and other tissues. While estrogen is traditionally associated with reproduction and sexual behavior in females,
Dusti A. Shay, Victoria J. Vieira-Potter, Cheryl S. Rosenfeld, Cheryl S. Rosenfeld, Cheryl S. Rosenfeld   +4 more
doaj   +1 more source

Androgenetic alopecia: a review [PDF]

, 2017
Purpose Androgenetic alopecia, commonly known as male pattern baldness, is the most common type of progressive hair loss disorder in men. The aim of this paper is to review recent advances in understanding the pathophysiology and molecular mechanism
Caro, Gemma, Fortuna, MARIA CATERINA, Lenzi, Andrea, Lolli, Francesca, Lombardo, Francesco, Pallotti, Francesco, Rossi, Alfredo, Sansone, Andrea   +7 more
core   +1 more source